Epic Sciences

02.02.2019 Back to Event Listings

ASCO GU 2019

The Epic Sciences team will be attending the ASCO Genitourinary Cancer Symposiums Annual Meeting in San Francisco, CA from February 14 - 16, 2019.

Thursday, February 14th - 11:30 AM-1:00 PM and 5:30 PM–6:30 PM

Poster Session A: Prostate Cancer and Trials in Progress.

Board K4 - Morphology-predicted, large-scale transition (LST) number in circulating tumor cells (CTC) as a biomarker of chromosomal instability (CIN) to assess early resistance to standard of care (SOC) drugs in mCRPC.

Authors: Howard Scher, MD, FASCO et al.

Board N4 - A phase II trial in progress: Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency (HRD) phenotype or BRCA defects. 

Authors: Simon Chowdhury, MD, PhD et al.

Friday, February 15th - 12:15 PM-1:45 PM and 5:15 PM–6:15 PM

Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, Testicular, and Adrenal Cancers.

Board F14 - Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi).

Authors: Zishuo Hu et al.

Board G11 - Circulating cellular biomarkers associated with delayed time to progression among bladder cancer patients treated with immune checkpoint inhibitors. 

Authors: Vadim Koshkin, MD et al.

Please contact us if you would like to set up a meeting while we are there.